Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 11/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4525533 | 1.00 | WNT3A (0.52) | WNT3APTPN1PTPN2ROCK2ROCK1 | |
| SCHEMBL4525453 | 0.87 | ROCK2 (0.53) | ROCK2ROCK1HDAC8 | |
| SCHEMBL4525931 | 0.87 | ROCK2 (0.53) | ROCK2ROCK1HDAC8 | |
| SCHEMBL4527153 | 0.81 | WNT3A (0.44) | WNT3AROCK2ROCK1 | |
| SCHEMBL4530261 | 0.81 | WNT3A (0.44) | WNT3AROCK2ROCK1 | |
| SCHEMBL4515624 | 0.80 | WNT3A (0.58) | WNT3APTPN1PTPN2ROCK2ROCK1 | |
| SCHEMBL4514904 | 0.80 | WNT3A (0.58) | WNT3APTPN1PTPN2ROCK2ROCK1 | |
| SCHEMBL2686192 | 0.78 | NOX1 (0.55) | ROCK1GPR142 | |
| SCHEMBL4520956 | 0.73 | LMNA (0.44) | ROCK2ROCK1 | |
| SCHEMBL4528957 | 0.73 | LMNA (0.44) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | WNT3A 3461/4885PTPN1 1462/4885PTPN2 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.